The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study.

All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w).

Inclusion Criteria:

• Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
• Has successfully completed participation in their parent latozinemab study.
• Female participants must be nonpregnant and nonlactating.
• Male participants must agree to acceptable contraception use.

Exclusion Criteria:

• Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
• Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.

This is an open label continuation study